Clinical Trial Update: Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study [Phase 3]

View source ↗

Summary

Phase 3 trial update on canakinumab for acute gout flares and prevention in patients unable to use NSAIDs or colchicine, including a 12-week extension and an op…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Gout | Phase 3 | Status: COMPLETED | Results posted: 2011-11-18